PGN-650-I124

N/A

Report date: 2025/11/24 17:28:01

Base Information

Drug NamePGN-650-I124
Drug Alias NamePGN-650-I124124I-PGN-650NIR-PGN-650PGN-650-124-I
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment +[7] 
Mechanisms of ActionRadionuclide imaging enhancersTomography enhancers
TargetsPhosphatidylserine
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAffitechThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAvid Bioservices Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A